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Christa Baumstark-Khan
Cellular Biodiagnostics, Department of Radiation Biology, Institute of Aerospace Medicine, German Aerospace Centre (DLR), 
Cologne, Germany
Charged particles, such as carbon ions, bear the promise of a more effective cancer 
therapy. In human spaceflight, exposure to charged particles represents an import-
ant risk factor for chronic and late effects such as cancer. Biological effects elicited 
by charged particle exposure depend on their characteristics, e.g., on linear energy 
transfer (LET). For diverse outcomes (cell death, mutation, transformation, and cell-cycle 
arrest), an LET dependency of the effect size was observed. These outcomes result from 
activation of a complex network of signaling pathways in the DNA damage response, 
which result in cell-protective (DNA repair and cell-cycle arrest) or cell-destructive (cell 
death) reactions. Triggering of these pathways converges among others in the activation 
of transcription factors, such as p53, nuclear factor κB (NF-κB), activated protein 1 
(AP-1), nuclear  erythroid-derived 2-related factor 2 (Nrf2), and cAMP responsive element 
binding protein (CREB). Depending on dose, radiation quality, and tissue, p53 induces 
apoptosis or cell-cycle arrest. In low LET radiation therapy, p53 mutations are often 
associated with therapy resistance, while the outcome of carbon ion therapy seems to 
be independent of the tumor’s p53 status. NF-κB is a central transcription factor in the 
immune system and exhibits pro-survival effects. Both p53 and NF-κB are activated after 
ionizing radiation exposure in an ataxia telangiectasia mutated (ATM)-dependent man-
ner. The NF-κB activation was shown to strongly depend on charged particles’ LET, with 
a maximal activation in the LET range of 90–300 keV/μm. AP-1 controls proliferation, 
senescence, differentiation, and apoptosis. Nrf2 can induce cellular antioxidant defense 
systems, CREB might also be involved in survival responses. The extent of activation 
of these transcription factors by charged particles and their interaction in the cellular 
radiation response greatly influences the destiny of the irradiated and also neighboring 
cells in the bystander effect.
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iNTRODUCTiON
Understanding the cellular radiation response is an essential prerequisite for improving cancer 
radiotherapy, including carbon ion therapy. The same holds true for the risk assessment of astronauts’ 
and for effective countermeasure development.
Radiotherapy of cancer with protons and carbon ions profits from a more precise dose deposition 
with charged particle beams in the tumor and in the case of carbon ions, also a higher biological 
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effectiveness in cell killing compared to conventional radio-
therapy. There are hints that with carbon ions, cell killing is less 
dependent on factors such as oxygen concentration and altera-
tions in cellular signaling pathways such as the p53 pathway.
Astronauts on exploration missions are subjected to not only 
greater amounts of natural radiation in space than they receive on 
Earth but also to a differing radiation quality, which can result in 
immediate and long-term risks. Besides protons and α-particles, 
heavier nuclei are part of the radiation field encountered in space. 
Heavy ions represent an important part of galactic cosmic rays 
because of their high biological effectiveness (1).
The radiation quality of energetic ions, including protons, 
α-particles, and heavy ions, is usually characterized by the linear 
energy transfer (LET) in matter which is a measure of the aver-
age energy transferred when an ionizing particle passes through 
matter and loses energy (2). Indirectly, it gives information about 
the ionization density along the particle track.
In the cellular response to radiation, several sensors detect the 
induced DNA damage and trigger signal transduction pathways, 
resulting in cell death or survival with or without mutations (3, 
4). The activation of several signal transduction pathways by ion-
izing radiation (IR) results in altered expression of series of target 
genes. The promoters or enhancers of these genes may contain 
binding sites for one or more transcription factors, and a specific 
transcription factor can influence the transcription of multiple 
genes. A meta-analysis revealed that two p53-dependent genes, 
GADD45 (especially GADD45α) and CDKN1A, and genes 
associated with the NER pathway (e.g., XPC) are consistently 
upregulated by IR exposure (5). Importantly, the transcribed 
subset of target genes is critical for the decision between resuming 
normal function after cell-cycle arrest and DNA repair, entering 
senescence, or proceeding through apoptosis in cases of severe 
DNA damage (5) and thereby for the cellular destiny and for the 
outcome of cancer radiotherapy. The changes in gene expression 
induced by IR via transcription factors depend on dose, dose rate, 
time after irradiation, radiation quality, cell type, inherited or 
accumulated mutations in signaling pathways, cell-cycle phase, 
and possibly on other factors (Table  1). Twelve years ago, the 
transcription factors to be activated after exposure to clinically 
relevant doses of IR were summarized, resulting in the short list 
of p53, nuclear factor κB (NF-κB), and the specificity protein 1 
(SP1)-related retinoblastoma control proteins (RCPs) (6). In this 
review, the role of transcription factors in the cellular response to 
IR is summarized with a special focus on charged particles as far 
as data are available.
p53
The transcription factor TP53 (p53) was first described in 1979 
(7), and many names have been attributed to the factor that 
belongs to the class of tumor suppressor genes. The transcription 
factor was called “an acrobat in tumorigenesis” (8), the “good and 
bad cop” (9), a “death star” (10), and even the “guardian of the 
genome” (11). p53 is involved in the regulation of cellular sur-
vival, immune responses, and inflammation, resulting in eminent 
importance in cancerogenesis and inflammation. Nowadays, it 
is known that defects in p53 are directly or indirectly involved 
in the majority (>50%) of human cancers as described by the 
International Cancer Genome Consortium (ICGC).
The human p53 gene is located on the short arm of chromosome 
17 (17p13) and the protein size is 393 amino acids (~43 kDa). 
It is composed of several domains: the N-terminus contains a 
transactivation domain for downstream gene activation (1–43). 
A proline rich domain follows that mediates the response to DNA 
damage through apoptosis (58–101). The DNA-binding region or 
domain (DBD) is next (102–292) followed by an oligomerization 
domain (320–355) that interacts with other p53 monomers (p53 
is capable of tetramerize). The C-terminus (356–393) is leucine 
rich and contains three putative nuclear localization signals 
(NLS) and so-called nuclear export signals (NES). It is postulated 
that when oligomerization occurs, NES are masked and p53 is 
retained in the nucleus. The DBD is the core domain, and it is 
composed of a variety of structural motifs. Single mutations 
within this domain can cause a major conformational change. 
There are in total 12 isoforms of p53 in humans discovered until 
now (12).
p53 has been recognized as an important checkpoint protein 
in the DNA damage response (DDR), which transcriptionally 
controls target genes involved in multiple response pathways 
that are as diverse as cell-cycle arrest and survival or death by 
apoptosis (13). It is thereby important for explaining the diversity 
of cellular responses to IR exposure. p53 has a short half-life 
and is stabilized in response to a variety of cellular stresses after 
phosphorylation by ataxia telangiectasia mutated (ATM) (13). 
After exposure to IR, phosphorylation of the serine residues 15 
and 20 on p53 by checkpoint kinase 2 (CHK2) reduces its binding 
to MDM2, which in its bound state targets p53 for degradation 
by the proteasome pathway (Figure 1). Thus, dissociation of p53 
from MDM2 prolongs the half-life of p53 (14). Other proteins, 
such as Pin 1, Parc, and p300, and p300/CBP-associated factor 
(PCAF) histone acetyltransferases regulate the transactivation 
activity of p53 (13). For efficient repair, especially in non-dividing 
cells, cellular levels of deoxyribonucleotides are increased dur-
ing the DDR by p53-dependent transcriptional induction of the 
ribonucleotide reductase RRM2B (p53R2) (15).
It is accepted that the severity of DNA damage is the critical 
factor in directing the signaling cascade toward reversible cell-
cycle arrest or apoptosis (13, 15). As part of the signaling cascade, 
the abundance of p53 protein, specific posttranslational modifi-
cations, and its interaction with downstream effectors, such as 
GADD45α or p21, may be responsible for directing the cellular 
response at this decision point (14).
Recently, Gudkov and Komarova (16) proposed that after total 
body irradiation (TBI) of mice severe damage occurs in tissues 
prone to p53-dependent apoptosis [the apoptosis response of p53 
after X-irradiation was already shown in murine experiments 
1996 by Norimura et al. (17)], such as the hematopoietic system, 
hair follicles, and oligodendroblasts in the spinal cord. Other 
tissues, such as the vascular endothelial cells (ECs) of the small 
intestine react to p53 activation by cell-cycle arrest and activation 
of DNA repair (16). Connective tissues and epithelial cells usually 
respond with growth arrest to p53 activation (16). The authors 
conclude from animal models that p53 is the key component of 
the toxicity of IR or radiomimetic (DNA damaging) drugs. It 
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TABLe 1 | Transcription factor activation by ionizing radiation.
experimental model Radiation quality Dose Method effect Reference
p53
H1299 (originally p53 null) X-rays 2–5 Gy Colony-forming ability (CFA) assay, acridine orange/
ethidium bromide staining, Western blot, quantitative 
real time RT-PCR (RT-qPCR)
Wildtype p53 cells: higher sensitivity compared to 
p53 null or mutated p53 cells
(172)
12C 290 MeV/u 2–5 Gy Low LET radiation ⇒ p53-dependent apoptosis
High LET ⇒ p53-independent apoptosis
A549, AGS, and MCF-7 X-rays 0–12 Gy RT-qPCR, Western blot, flow cytometry, luciferase 
reporter assay, CFA assay
miR-375 overexpression ⇒ p53 expressions ⇓ (173)
Etoposide 0–100 μM Radiosensitivity ⇓
HCT116 (colorectal cells) p53 wt and 
ko cells 
X-rays 0–8 Gy Viability assay (transwell co-culture), micronuclei and 
apoptosis evaluation, beta-galactosidase staining, 
RT-qPCR
Low doses: no difference between cell lines (174)
Higher doses: significant differences, e.g., 
micronuclei ⇑ and apoptotic cells ⇑ in p53−/− cells, 
p53+/+: high levels of senescence
Lung epithelial cells α-particles (238Pu)
X-rays
0–1.2 Gy
0–2.5 Gy
Flow cytometry p53 expression levels ⇑ (175)
HCT116 12C 290 MeV/u 0–3 Gy CFA assay, flow cytometry, iimmunofluorescence X-rays ⇒ higher sensitivity and apoptosis ⇑ in p53+/+ 
cells
(176)
X-rays 0–8 Gy C-ions ⇒ no difference of sensitivity (mitotic 
catastrophe ⇑ in p53−/− cells, apoptosis ⇑ in p53+/+ 
cells)
NF-κB
Human, mouse, rat, hamster normal, 
transformed and tumor cell lines and 
primary cells, animal models (rat, mouse)
X-rays, γ-radiation, 
protons, α-particles, 
Fe ions, C ions, Ar ions
0.05–100 Gy EMSA, Western blot, immunofluorescence, reporter 
assays, oligonucleotide enzyme-linked immunosorbent 
assay (ELISA)
Dose, cell line/cell type, and radiation quality-
dependent activation
(70)
Nrf2
NIH-3T3
MCF7-AREc32
Embryonic fibroblasts from wt and Nrf2 
ko mice
γ-radiation 
137Cs source
2–8 Gy, 10 Gy Luciferase assay, RT-qPCR, Western blot, CFA assay, 
ROS measurement (H2DCFH-DA)
No short-term activation of Nrf2 activation
Late activation of Nrf2
Nrf2 activation after fractionated irradiation
(88)
PC3 and DU145 prostate cancer cell 
lines
γ-radiation 
60Co source
1–10 Gy Electrophoretic mobility shift assay (EMSA), RT-qPCR Differences in basal Nrf2 expression determine 
resistance to irradiation
(99)
4 and 8 Gy Knockdown (kd) of Nrf2 and heme oxygenase-1 (HO-1) 
expression using short hairpin RNA (shRNA)
High basal Nrf2 activity ⇒ Nrf2 activity ⇑, target gene 
expression ⇑ (DU145 cells) ⇒ higher radioresistance 
than PC3 cells
Knockdown of Nrf2 ⇒ cell death ⇑
Murine T-cell lymphoma cell line EL-4 γ-radiation  
60Co source
4 Gy shRNA-kd, RT-qPCR, EMSA ERK and Nrf2 interact in radioresistance of EL-4 cells (102)
Dermal fibroblasts from wt mice and Nrf2 
and Keap1-KO mice
UV-A-UV-B radiation 10.000 mJ/cm2 Western blot, immunofluorescence, flow cytometry UV-A, but not UV-B, induces Nrf2 activity, cellular 
survival depends on Nrf2
(103)
(Continued)
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experimental model Radiation quality Dose Method effect Reference
C57BL/6, CD-1, and SJL/C57BL/6 
CD45.1 mice
γ-radiation 6.9, 7.0, 7.1, 7.25, 
7.3, 10 Gy TBI
RT-qPCR Interplay between Nrf2 and Notch signaling, 
Nrf2 mediates Notch signaling and increases 
hematopoietic stem cell function
(106)
Mx-Cre-Keap1flox/flox 137Cs source
CMVCre-Keap1flox/flox 12C6+ ions 2 Gy RT-qPCR of Nrf2 downstream genes NAD(P)H quinine 
oxidoreductase 1 (NQO1), HO-1, gamma-glutamyl 
cysteine synthetase (γ-GCS), immunofluorescence, 
Western blot
NQO1, HO-1, γ-GCS ⇑ in curcumin-pretreated mice (108)
Keap1flox/flox mice
HCEC CT7s cells (immortalized colon 
epithelic cells)
γ-radiation 137Cs source 
(cells)
4–5 Gy Immunohistochemistry, Western blot, subcellular 
fractionation, immunofluorescence, assay for 
chromosomal aberrations at metaphase, shRNA 
against Nrf2, DNA fiber assay, ChIP qPCR
Nrf2 enhances DDR and reduces number of DNA 
DSB
(109)
C57BL/6 wt mice X-rays (mice) 7.5–10 Gy TBI Nrf2 ⇒ 53BP1 expression ⇑
EA.hy926 and HMVEC cells Photons from linear 
accelerator
0, 0.3, 0.5, 0.7, 1 Gy RT-qPCR, flow cytometry, Western blot, enzyme 
activity of glutathione peroxidase, EMSA
Non-linear activation of Nrf2 and target genes (107)
Nrf2 activation prior to irradiation ⇒ cell adhesion ⇑
Nrf2 expression and binding to DNA lowest at 0.5 Gy
CReB
Human U1-Mel cell line 60Co γ-rays 4.5 Gy EMSA with nuclear extracts CREB DNA binding ⇑ (123)
Jurkat leukemic T cell line 10 MV X-rays 1.5 and 6 Gy Western blot CREB phosphorylation ⇑ (115)
K562 erythroleukemia cells 10 MV X-rays 1.5 and 15 Gy Western blot CREB phosphorylation ⇑ (119)
Chinese Hamster V79 cells 12C5+ ions 0.1 and 1 Gy Western blot p44/42 MAPK ⇑ (125)
AG1522 human diploid skin fibroblasts α-particles (238Pu source) 0.01, 0.05, and 
0.10 Gy
Western blot p38 MAPK and ERK 1/2 ⇑ (126)
AP-1
AG1522 human diploid skin fibroblast α-particles (238Pu source) 0.003 and 0.006 Gy EMSA AP-1 DNA-binding activity ⇑ (126)
MRC5CV1 normal human fibroblasts 137Cs γ-rays 20 Gy Western blot c-jun phosphorylation ⇑ (131)
EMSA AP-1 DNA-binding activity ⇑
ROS 17/2.8 osteoblasts X-rays 5 Gy EMSA with supershift AP-1 DNA-binding activity ⇑ (132)
Spontaneously immortalized human 
breast epithelial cell line MCF-10F
α-particles, LET 
150 keV/μm
6 and 1.2 Gy Northern blot and immunochemical protein staining c-jun, c-fos, FRA1 RNA, and protein expression ⇑ (135)
C57BL/6J mice 56Fe ions, 1000 MeV/n, 
LET 148 keV/μm
1.6 Gy SOD 1/2 and catalase activity, NADPH oxidase activity 
assay and immunohistochemistry of p-H3
SOD 1/2, catalase, NADPH oxidase and mitogenic 
activity ⇑
(98)
Sp1
Normal human diploid fibroblasts 6 MV X-rays 0.5, 2.5, 5, 10, 20, 
40 Gy
Western blot Sp1 expression and phosphorylation ⇑ (141)
U1-Mel cells 137Cs γ-rays 3 and 4.5 Gy EMSA and Western blot Sp1 DNA binding and phosphorylation ⇑ (142)
TABLe 1 | Continued
(Continued)
Cellular preservation and genetic stability
IR
Cell cycle arrest Apoptosis
p53
Cell cycle restart
DNA repair
MDM2
DNA damage
Hypoxia
Cell cycle disturbances
p53
Death and elimination 
of damaged cells
FiGURe 1 | The p53 pathway. p53 is under normal conditions inactivated 
by murine double minute 2 (MDM2). When, e.g., DNA damage occurs, p53 
dissociates from its regulatory MDM2 complex by various pathways. In this 
active state, phosphorylated p53 will induce a cell-cycle arrest to permit 
either repair and therefore survival of the cell or induce apoptosis to eliminate 
a damaged cell.
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thereby contributes to the hematopoietic component of the acute 
radiation syndrome and leads to severe adverse effects of cancer 
treatment (16).
p53-dependent GADD45α upregulation may play a role in 
apoptosis by activating the c-Jun N-terminal kinase (JNK) and/
or p38 mitogen-activated protein kinase (MAPK) signaling path-
ways (18). Besides GADD45α, p53 regulates the expression of 
other proteins involved in apoptosis, including membrane-bound 
proteins, such as Fas/CD95, TP53 apoptosis effector related to 
PMP22 (PERP), and KILLER/DR5, cytoplasm-localized proteins, 
such as p53-inducible death domain-containing protein (PIDD) 
and PIGs, and mitochondrial proteins, such as BAX, NOXA, 
PUMA, p53Aip1, and BID (13, 14). The induction of these pro-
apoptotic genes seems to be tissue specific (13). p53 also directly 
interacts with BAX, BCL-XL, and BCL-2 at the mitochondrial 
membrane (14).
So far, p53 plays a crucial role in the cellular radiation 
response. In future, the treatment of patients suffering from 
cancer will be personalized; this means that the combination of 
cytostatic agents and radiotherapy has to be individualized also 
depending on the tissue affected. For colorectal carcinoma cell 
lines, many tests are being performed with distinct agents where, 
e.g., gemcitabine, paclitaxel, or irinotecan are used in order to 
optimize the treatment results in combination with carbon ions. 
It has been already shown that after C-12 ion irradiation in cells 
lacking p53, paclitaxel and gemcitabine were very effective as 
well as irinotecan on p53 wild-type (wt) cells (19). Nevertheless, 
a problem with targeting the p53 pathway as a helping tool in can-
cer therapy by activation and thereby unleashing the protective 
attitudes of this pathway is that in hematological malignancies 
IR
AP-1
JNK c-jun c-fos
ROS
ATM
ATM PATM DNA-PK
PKA/
PKB
ERK/
MAPK CREB
CRE
Cyclin-A
Cyclin-D1
COX-2
Cell cycle progression
Proliferation
YAPp73
pro-apoptotic 
genes
Apoptosis
p53
c-fos
TRE
DNA repair
c-abl
P
P
Sp-1
P
cytoplasm nucleus
P
FiGURe 2 | Activation of the transcription factors CReB, AP-1, SP1, 
p73, and YAP upon irradiation ionizing radiation (iR) can activate 
protein kinase A (PKA) and B (PKB) as well as eRK/MAPK in the 
cytoplasm. Exposure to IR can produce reactive oxygen species (ROS) in 
the cytoplasm and nucleus and DNA double-strand breaks (DNA DSB) in the 
nucleus. PKA/PKB, ERK/MAPK, and ATM can phosphorylate CREB, which 
then translocates into the nucleus to bind CRE elements in order to express 
pro-survival proteins. ATM and DNA-PK can phosphorylate c-abl, which in 
turn phosphorylates YAP. Phosphorylated YAP acts together with p73 to 
stimulate expression of pro-apoptotic genes. ATM and DNA-PK can further 
induce Sp1, which can act pro-apoptotic by inducing p53 or pro-survival by 
regulating the DNA damage response and inducing DNA repair. IR-induced 
ROS can activate JNK to phosphorylate the AP-1 complex, thereby initiating 
DNA binding to TRE genes. Expression of TRE genes leads to induction of 
DNA repair and promotion of cell-cycle progression.
Hellweg et al. Transcription Factors and Charged Particles
March 2016 | Volume 6 | Article 616Frontiers in Oncology | www.frontiersin.org
and thereby modulate environment-induced gene expression. 
Besides immune  modulating agents and pathogen-derived agents 
(lipopolysaccharides), a variety of other cellular stress factors are 
able to induce this pathway, such as cytokines, phorbol esters, 
viruses, ultraviolet (UV) radiation, reactive oxygen species 
(ROS), necrotic cell products, growth factor depletion, hypoxia, 
heat shock, and IR (38–41).
In the inactive state, NF-κB is retained in the cytoplasm by the 
inhibitory IκB proteins (Figure 4), which controls nuclear trans-
location of NF-κB by masking its NLS (42, 43). IκB proteins bind 
through their ankyrin repeat domain (ARD) to NF-κB. In their 
free state, IκB proteins are unstable and rapidly degraded, while 
binding to NF-κB strongly increases their stability (43). The three 
(NFκBIA, NFκBIB, and NFκBIE) genes code for the canonical 
IκB proteins, IκBα, IκBβ, and IκBϵ (Figure 4) (43). The p50:p65 
heterodimer is mainly bound by IκBα. p105 and p100 proteins, 
which are involved in the alternative NF-κB pathway, contain the 
inhibitory part already in their C-terminal region in addition to 
the NF-κB part in the N-terminal half. Two novel IκBs (IκBζ and 
BCL-3) were described. BCL-3 is a non-inhibiting IκB family 
member that acts as transcriptional co-activator for p50:p50 and 
p52:p52 homodimers (44). Further novel atypical IκB proteins 
were recently reviewed by Arnemann et al. (45).
Upon activation, IκBα can be degraded by several proteases 
(46) and the released NF-κB translocates to the nucleus and 
there is a low incidence of p53 mutations. Here, maybe MDM2 
proteins can be addressed.
The bystander effect is a field that still needs to be understood 
and where experiments and the effects of a possible p53 response 
are barely recognized. First observations though, show that in 
mammalian cells lacking p53 in comparison to wt p53, the cells 
respond upon heavy ion exposure in the already known ways 
when directly irradiated (20). This fact is also to be taken into 
consideration when irradiation of patients is to be performed 
even though it does not play a major role, since the main goal 
is still targeting and eliminating the malignant tumors in an 
efficient manner.
The tyrosine kinase c-abl is a functional analogous to p53 
in regulation of programmed cell death and DNA repair (21) 
interacting with p53 indirectly through modification of upstream 
regulators [homeodomain-interacting protein kinase 2 (HIPK2)] 
(22). C-abl is the ubiquitously expressed product of the cellular 
homolog of the transforming gene of Abelson murine leukemia 
virus (v-abl) shuttling between cytoplasm and nucleus of the cell 
(21, 23). Cytoplasmic c-abl is assumed to function in association 
with the F-actin cytoskeleton while nuclear c-abl participates in 
cell-cycle regulation, DDR, and apoptosis (23). Sparsely ionizing 
leads to an activation of c-abl (21, 24, 25) via phosphorylation 
by ATM at Ser-465 (26) and by DNA-dependent protein kinase 
(DNA-PK) (21, 23). It can function as a negative regulator of DNA 
repair progression, inhibiting DSB re-joining and downregulating 
γH2AX, decreasing the recruitment of DNA repair factors to the 
damage site (21), or c-abl can phosphorylate DNA PK and Rad51 
to abolish their binding to DNA, thereby impeding their function 
(21, 25). It can also promote apoptosis with a direct influence on 
the p73-dependent DDR by phosphorylating the YES-associated 
protein (YAP). Upon phosphorylation, YAP acts together with 
p73 on pro-apoptotic gene targets (Figure 2) (21, 22).
In response to densely IR, c-abl has been surmised to partake 
in a p53-independent induction of apoptosis. In the model 
described, c-abl activates caspase 9 via phosphorylation at Tyr 
153, initiating the cleavage of caspase 3 as a point of no return in 
apoptosis induction (27).
In summary, a potential role in the cellular radiation response 
can be attributed to c-abl as mediator of apoptosis and coordina-
tor of DNA repair. Albeit greater focus on densely IR, such as 
carbon therapy, has to be introduced to fully conclude its role for 
this radiation quality.
NUCLeAR FACTOR κB
Although several genes induced by IR are p53-regulated, the 
majority are p53-independent (28–31), with the transcription 
factor NF-κB playing a contributing role (29, 31).
NF-κB/Rel proteins comprise a family of structurally related 
eukaryotic transcription factors that are involved in the control 
of a large number of cellular and organismal processes, such 
as immune system development and performance, inflamma-
tion, developmental processes, cellular growth, and apoptosis 
(32–35). Homo- or heterodimers of NF-κB1 (p50/p105), 
NF-κB2 (p52/p100), RelA (p65), RelB, or c-Rel (Figure  3) 
can be activated in response to hundreds of agents (36–38) 
Gene Protein Polypeptide Stimuli that induce 
degradation
NFKBIA
TNF, LPS, IL-1, 
Antigens (TCR, 
BCR)
NFKBIB
NFKBIE
NFKB1 LPS (in B-cells)
NFKB2 LT-β, CD40, BAFF,
RANKL
SRD
ARDs
SRD
ARDs
SRD
ARDs
SRD
ARDs
RHD
SRD
ARDs
RHD
p100
p105
I
I B
I B
FiGURe 4 | The members of the inhibitor of NF-κB (iκB) family. IκB 
proteins contain ankyrin repeat domains (ARDs) and signal response domains 
(SRDs) and are degraded in response to different signals (BCR, B-cell 
receptor; TCR, T-cell receptor; LPS, lipopolysaccharide; LT-β, lymphotoxin-β; 
BAFF, B-cell-activating factor; RANKL, receptor activator of NF-κB ligand). 
The ARDs on p105 and p100 (which are proteolytically processed to p50 and 
p52 NF-κB monomers, respectively) can act to self-inhibit p50 and p52. 
p100 can also form a multimeric complex in which it can inhibit other latent 
NF-κB dimers. Adapted from O’Dea and Hoffmann (43).
50 50
B p65 cRel RelB p52 p50
p65
cRel
RelB
p52
p50
cRelcRelcRel RelB
RelBRelB
p52
p52
p52
p52cRel
RelBDNA binding &transcription activation
DNA binding, but no 
transcription activation
No DNA binding 
p50
p65
p50
p65
p50
p65
p50
p65
p50
p65 p50p65 cRel RelB p52
cRel
RelB
p52
Gene Protein Polypeptide
RELA
CREL
RELB
NFKB1
NFKB2
RHD TAD
cRel RHD TAD
RelB RHD TAD
RHD
p52 RHD
A
p50
p65
FiGURe 3 | The members of the NF-κB family. (A) NF-κB subunits each 
contain a Rel homology domain (RHD) for dimerization and DNA binding. p65 
(RelA), c-Rel, and RelB bear transcriptional activation domains (TAD). (B) The 
5 NF-κB monomers can associate to 15 potential dimers. Of these, nine can 
bind DNA and activate gene transcription (light gray), three (the p50 or p52 
only containing dimers) bind DNA but do not activate transcription (medium 
gray), and three do not bind DNA (dark gray). Adapted from O’Dea and 
Hoffmann (43).
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binds to κB or κB-like DNA motifs [NF-κB response elements, 
NREs with the consensus sequence GGGRNNN(N)YCC]1 
initiating gene transcription. NREs have been identified in the 
1 N, any nucleotide, R, purine, and Y, pyrimidine.
promoter or enhancer regions of more than 200 genes, including 
a number of IκBs, growth factors, proinflammatory cytokines 
(TNF-α, IL-1, IL-6) and enzymes (cyclooxygenase-2, COX-2), 
chemokines (IL-8/CXCL8; monocyte chemotactic cytokine 1, 
MCP-1/CCL2), angiogenic factors (vascular endothelial growth 
factor, VEGF), degradative enzymes (matrix metalloproteinases, 
MMPs), and adhesion molecules (intercellular adhesion mol-
ecule-1, ICAM-1; vascular cell adhesion molecule-1, VCAM-1; 
E-selectin). These target genes are involved in inflammation, 
innate immune responses, angiogenesis, tumor progression, and 
metastasis in various cancers and fibrosis (39, 44, 47, 48). NF-κB 
regulated expression of cytokines and extracellular matrix 
proteases after heavy ion exposure might contribute to extra-
cellular matrix remodeling (49). Activation of NF-κB by high 
radiation doses (1–10 Gy) could contribute to the inflammatory 
response observed, e.g., in the developing brain after radiation 
exposure (50).
In addition, NF-κB also regulates the expression of many genes 
whose products are involved in the control of cell proliferation 
and cell death (51). In a cell culture model, it has been found that 
ATM plays a role in sustained activation of NF-κB in response 
to DNA DSB (52, 53), probably by its PI-3-kinase-like activity 
(54). Activation of the NF-κB pathway does not only protect cells 
from apoptosis after treatment with various genotoxic agents via 
expression of anti-apoptotic proteins, such as Bcl-2, GADD45β, 
TRAF-1,  TRAF-2, cIAP-1, and cIAP-2 (55), but also gives 
transformed cells a growth and survival advantage and further 
renders tumor cells therapy resistant (56). NF-κB acts also as a 
transcriptional enhancer for the protective enzyme manganese 
superoxide dismutase (Mn-SOD) and might thereby contribute 
to therapy resistance. NF-κB also enhances the expression of 
degradative enzymes supporting the idea that it makes a major 
contribution to tumor progression and metastasis in various 
cancers (48). Therefore, NF-κB was identified quite early as 
potential target of innovative cancer therapies (57). Due to this 
anti-apoptotic effects NF-κB activation, it is an important stress 
response that may modulate the outcome of chemotherapy- and 
radiotherapy-induced toxicity.
For cells of the immune system, a misdirection of the NF-κB 
correlated process that normally creates immunoglobulin 
diversity might result in increased survivability of cells with 
oncogenic chromosomal translocations that prevent apoptosis 
and promote proliferation of pre-malignant cells. Constitutive 
activity of NF-κB or its over-expression has been reported for 
many human cancer cells (including breast cancer, colon cancer, 
prostate cancer, and lymphoid cancers) and can cause malignant 
changes in lymphoid cells in tissue culture.
NF-κB–Rel complexes can be activated and be functional 
in three different subpathways in different cells and tissues: the 
canonical or classical pathway, the alternative or  non-canonical 
pathway, and the genotoxic stress-induced  pathway (58–60).
In the canonical or classical pathway, the signals for activa-
tion of NF-κB are generated by cytokines, e.g., TNF-α or IL-1, 
by growth factors, by ligands of toll-like receptors (TLRs) or by 
antigens, which bind to the T-cell receptor (TCR) or the B-cell 
receptor (BCR). The NF-κB is mostly composed of p50:p65 and 
p50:c-Rel dimers.
FiGURe 5 | The canonical or classical NF-κB pathway. The binding of 
TNF-α to TNF-R leads to a rapid recruitment of TRADD, RIP1, TRAF2, 
TRAF5, c-IAP1, and c-IAP2. Formation of this complex triggers TRAF2/5 and 
c-IAP1/2 to catalyze polyubiquitination of RIP1 and autoubiquitination of 
TRAF2 and/or c-IAP1 (not shown). Modified RIP1 then recruits the TAK1/
TAB1/TAB2 (only TAK1 shown) and IKKα/IKKβ/NEMO complexes, leading to 
TAK1 activation and TAK1-mediated activation of IKKβ. Upon IL-1 stimulation 
of IL-1R, proteins, such as MyD88, Tollip, IRAK-1, and IRAK-4, are recruited, 
leading to IRAK1/4-dependent binding of TRAF6 and Pellino. TRAF6 then 
undergoes autoubiquitination, whereas Pellino catalyzes IRAK1 ubiquitination. 
Ubiquitinated TRAF6 in turn serves as a platform to recruit the TAK1/TAB1/
TAB2 complex, resulting in TAK1 activation and finally IKKβ activation. TLR 
signaling can be MyD88 dependent or independent through TRAM, TRIF, and 
RIP. Activated IKK then phosphorylates IκBα, resulting in its ubiquitination 
and degradation. This IκBα degradation allows p50:p65 dimer to translocate 
to the nucleus and activate the expression of genes involved in inflammation, 
innate immunity, and cell survival. Ultraviolet (UV) irradiation reduces IκB levels 
via activation of GCN2 or PERK, which phosphorylate the initiation factor 
elF2α, and via casein kinase 2 (CK2) and thymidine kinase (TK). 
Phosphorylated elF2α blocks IκB synthesis. The BCR and TCR are 
expressed by B- and T-lymphocytes and do not act one the same cell. 
Adapted from O’Dea and Hoffmann (43) and Habelhah (44).
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A central event in the pattern of NF-κB complex activation 
(Figure 5) is the activation of IκB kinase (IKK). This is achieved 
via a complex pathway involving several adaptor proteins, 
ubiquitin ligases, binding proteins, and kinases, such as receptor-
interacting protein 1 (RIP1) and TNF-R-associated factor 2, 5, 
or 6 (TRAF2/5/6) (43, 44, 58–60), resulting in activation of IKK 
kinases (IKK-K). These kinases are responsible for phosphoryla-
tion of IKK and might be TGF-β-activated protein kinase 1 (TAK1) 
or MAPK kinase kinase 3 (MEKK3) after stimulation with TNF-α 
(44). The exact contribution of different kinases to IKK activation 
is not completely known, and redundancy in function may occur.
The IKK complex is composed of the two catalytic subunits, 
IKKα and IKKβ,2 and the regulatory subunit, IKKγ/NF-κB 
2 “The commonly used anti-inflammatory drugs aspirin and sodium salicylate exert 
their effects in part by acting as competitive inhibitors of the ATP-binding site of 
IKKβ” (63).
essential modulator (NEMO) (43). The activated IKK phos-
phorylates IκB at the serine residues 32 and 36 in the signal 
responsive domain and thereby targets IκB for ubiquitination 
(61). Phosphorylated IκB is polyubiquitinylated by the E3 
ubiquitin ligase containing β-TrCP and subsequently degraded 
by the 26S proteasome (43, 58, 59). Alternatively, IκB can be 
phosphorylated at tyrosine 42, which has the potential to con-
nect NF-κB directly to membrane receptor-associated tyrosine 
kinases (62).
Receptor signaling as described above in the canonical path-
way is often dependent on the synthesis of autocrine factors, such 
as cytokines (64).
In response to TNF-α, IκBα is rapidly degraded, followed by 
NF-κB-dependent resynthesis. Persisting stimulation by bind-
ing of TNF-α to its receptor (TNF-R) results in cycles of IκBα 
degradation and resynthesis (43). After TNF-α stimulation, the 
deubiquitinases A20 (or TNF-α-induced protein 3, TNFAIP3) or 
CYLD (gene mutated in familial Cylindromatosis)3 limit NF-κB 
activation (44, 65).
Activation of NF-κB after antigen binding to the TCR or BCR 
is mediated via activation of a phospholipase, which produces 
diacylglycerol, the activator of protein kinases C (PKC). PKC 
phosphorylates caspase recruitment domain 11 (CARD11), 
which then recruits other adaptor proteins – BCL-10 and MALT1 
forming the CBM complex4 with CARD11 in B-cells –  leading 
finally to phosphorylation of IKKβ and ubiquitination of NEMO 
(Figure 5). The activated IKK complex phosphorylates IκB, lead-
ing to its degradation, as described above (65).
The alternative or non-canonical pathway is involved in 
non-inflammatory signaling, e.g., in lymph node development 
and osteoclastogenesis (43). It starts at membrane receptors of 
the TNF-R superfamily with binding of B-cell activation fac-
tor (BAFF), lymphotoxin β (LTβ), CD40 ligand (CD40L), or 
receptor activator of NF-κB ligand (RANKL) (Figure 6). BAFF 
is critical for B-cell survival. LTβ is involved in lymph node 
development. CD40L has functions in the adaptive immune 
response, such as B-cell proliferation and differentiation, and 
immunoglobulin isotype switching. RANKL is essential for 
osteoclast differentiation from monocytes. Receptor–ligand 
binding results in activation of the IKKα-containing kinase 
complex by NF-κB-inducing kinase (NIK) and sometimes of the 
canonical IKKβ-containing complex (43, 44). TRAF2, c-IAP1, 
and c-IAP2 negatively regulate NIK via ubiquitination- and 
proteasome-dependent degradation (43). In unstimulated cells, 
NIK is marked for degradation by the TRAF2/c-IAP1/2 com-
plex. After receptor binding, NIK is stabilized and forms trimers 
that activate the IKKα complex.
In the alternative pathway, inactive NF-κB consists of 
a p100:RelB heterodimer. p100 in the p100:RelB complex 
3 Mutations in the CYLD gene are very rare, affected patients develop benign tumors 
on the skin due to increased cell growth mediated by overactive NF-κB (66).
4 Abnormal BCR signaling via CD79 and the CBM complex was observed in B-cell 
lymphomas (44, 65). Elevated MALT1 expression was also observed in lymphomas 
of mucosal-associated lymphoid tissue and might be explained in early stages by 
constant antigenic stimulation, and later by chromosomal translocations that posi-
tion the MALT1 gene under the control of heterologous promoters (38).
FiGURe 6 | The non-canonical or alternative NF-κB pathway. In 
unstimulated cells, TRAF3 constitutively recruits NIK to the TRAF2–c-IAP1/2 
complex, promoting c-IAP1/2-mediated K48-ubiquitination and degradation 
of NIK. Ligation of CD40 by CD40L leads to recruitment of the TRAF3–
TRAF2–c-IAP1/2 complex to the receptor, where TRAF2 catalyzes 
polyubiquitination of c-IAP1/2. It thereby promotes ubiquitin E3 ligase activity 
of c-IAP1/2 toward TRAF3, leading to proteasomal degradation of the latter. 
As a result, NIK can no longer be recruited to the TRAF2–c-IAP1/2 complex. 
This leads to stabilization and accumulation of newly synthesized NIK and its 
activation presumably via autophosphorylation, resulting in activation of the 
IKKα homodimer. Activated IKKα then phosphorylates p100, leading to 
proteasome-mediated processing of p100 to p52. The p52:RelB heterodimer 
then translocates to the nucleus and regulates transcription of target genes. 
CD40L promotes antibody isotype switching in mature B-cells, RANKL 
initiates osteoclastogenesis from precursor cells, BAFF induces immune cell 
survival and proliferation of B-cells, and LT-β regulates lymph node 
development. The receptors represented here on one cell are therefore 
restricted to distinct cell types and usually do not act in parallel. Adapted 
from O’Dea and Hoffmann (43) and Habelhah (44).
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is phosphorylated by the activated IKKα, which results in 
polyubiquitination of p100 and proteolytic degradation of the 
NF-κB-inhibiting C-terminal region of p100, releasing p52 (43). 
The resulting p52:RelB dimer translocates to the nucleus where 
it initiates transcription of genes involved in lymphoid organo-
genesis, immune cell survival, proliferation and maturation, and 
osteoclastogenesis (44). It results in low level nuclear transloca-
tion of NF-κB for hours or days (43).
Several cross-talk mechanisms of inflammatory and devel-
opmental NF-κB signaling via the canonical and the alternative 
pathway were described (43). For example, developmental 
signals can also activate canonical p50:p65 dimers bound to a 
dimer of p100 (called IκBδ) (43). The activated NIK as part of 
the alternative pathway may amplify canonical IKK activation 
(43). CD40L can activate the canonical and the alternative NF-κB 
pathway (65).
Recently, a role for RelB was suggested in the therapy resist-
ance of prostate cancer, which was explained by RelB-dependent 
induction of MnSOD (67).
DNA DSB in the cell nucleus can activate the genotoxin-induced 
pathway (68). Early studies supposed DNA-PK (69), PI3K, and 
MAPK (64) as mediators of radiation-induced NF-κB activation. 
In a cell culture model, it has been found that ATM plays a role 
in sustained activation of NF-κB in response to DNA DSB (52, 
53), probably by its PI-3-kinase-like activity (54). Activation of 
NF-κB via this pathway after exposure to IR was described in 
detail in a recent review (70). Briefly, DNA damage initiates the 
SUMOylation of NEMO by the sumo ligase PIASy in a complex 
with PIDD and RIP1, fostering NEMO’s localization in the 
nucleus (43). This nuclear SUMOylated NEMO associates with 
ATM with the result of monoubiquitination of NEMO, which is 
the signal for its cytoplasmic export (43). SUMOylated NEMO 
in complex with ATM therefore represents the long searched 
nuclear to cytoplasmic shuttle of the NF-κB activating signal 
(68). The protein ELKS binds to the cytoplasmic ATM–NEMO 
complex, enabling ATM-dependent activation of the canonical 
IKK complex (43). As described for the canonical pathway, IKK 
activation leads to IκBα degradation and NF-κB activation. The 
canonical p50:p65 heterodimer initiates gene transcription in the 
nucleus.
The role of the NF-κB pathway in cellular radiosensitivity was 
addressed by several studies (6). In a human ovarian cancer cell 
line, a human breast cancer cell line, and a murine melanoma 
cell line, radiation-activated NF-κB protected the cells from 
radiation-induced apoptosis (71). Inhibition of NF-κB activ-
ity can be achieved by overexpression of dominant-negative, 
phosphorylation-defective IκB. This has been reported to 
enhance the radiosensitivity of human fibrosarcoma cells (72), 
xenografted fibrosarcomas in mice (73) and human brain tumor 
cells (61, 74, 75), and to influence X-ray-induced mutations and 
apoptosis in human malignant glioma cells (76). For low LET 
radiation, NF-κB inhibition increased radiosensitivity of many 
cancer cells (6).
As activation of the NF-κB pathway is supposed to play a role 
in the negative regulation of both death receptor- and stress-
induced apoptosis (44), survival of cells with residual DNA dam-
age might thus be favored. Also, NF-κB’s role in the deregulation 
of inflammatory responses contributes to its tumor-promoting 
and progression-favoring characteristics (44).
Constitutive NF-κB activation is often found in human 
cancers, e.g., breast, thyroid, bladder, and colon cancer (56, 
77–80). It is thought to be important for maintaining survival 
of the cancer cells and for angiogenesis or chemoresistance 
(43, 81). The mechanisms that lead to constitutively activated 
NF-κB (82) and its critical role in tumor progression are cur-
rently only partly understood for some tumors. Mutations of 
the NFKBIA gene, which encodes IκBα or alterations of its 
expression level, might be an explanation for the increased 
NF-κB activity in tumors. In a recent study analyzing 790 
human glioblastomas, deletion or low expression of NFKBIA 
was associated with unfavorable outcomes (83), possibly result-
ing from uncontrolled NF-κB activity. In 37.5% of patients with 
Hodgkin lymphoma, mutations in the NFKBIA gene in the 
tumor cells were detected (84). Lake et al. (85) found NFKBIA 
mutations in 3 of 20 Hodgkin lymphoma patients (15%). In 
addition, a NFKBIA polymorphism (A to G variation, rs696 
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FiGURe 7 | The Nrf2–ARe pathway. Nrf2 is sequestered in the cytoplasm 
by Keap1 and targeted for ubiquitination by Cullin 3 and proteasomal 
degradation. Under conditions of oxidative stress or by chemical activators 
the thiol groups of cysteine residues of Keap1 are oxidized. This leads to the 
formation of disulfide bridges, which changes the conformation of Keap1 
which is unable to bind Nrf2 now. Nrf2 is no released from Keap1 and 
translocates to the nucleus by forming heterodimers with sMaf proteins. In 
the nucleus, the Nrf2–sMaf complex binds to antioxidant responsive element 
(ARE) sequence in the promoter region of Nrf2 target genes, leading to the 
expression of antioxidative enzymes, such as heme oxygenase, superoxide 
dismutase, and glutathione-S-transferase.
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in the 3′ UTR)5 was associated with colorectal cancer risk and 
poor treatment prognosis (86). In human adult T-cell leukemia 
or lymphoma associated with human T-cell leukemia virus type 
I, activation of the NF-κB pathway by the virus protein Tax via the 
canonical and the alternative pathway seems to be involved in the 
transformation process (47). Another mechanism of constitutive 
NF-κB activation was described in malignant melanoma cells: 
an elevated endogenous ROS production resulted in constitutive 
NF-κB translocation to the nucleus (87).
NUCLeAR eRYTHROiD-DeRiveD 
2-ReLATeD FACTOR 2
Nuclear erythroid-derived 2 (NF-E2)-related factor 2 (Nrf2) that 
binds the antioxidant DNA response element (ARE) to induce 
cellular antioxidant defense systems was shown to be activated 
5 days after irradiation (88). Nrf2 was identified in studies inves-
tigating the activation of detoxifying enzymes in the presence of 
electrophilic chemicals, such as ROS. It belongs to the cap “n” 
collar (CNC) family of basic leucine zipper (bZIP) transcription 
factors. In vertebrates, they include the p45–NF-E2 factors and 
the NF-E2-related factors Nrf1, Nrf2, and Nrf3. In fact, Nrf2 was 
first identified as a homolog of NF-E2 and was found to interact 
with NF-E2-binding sites (89). The natural repressor protein of 
Nrf2 is Kelch-like associated ECH-associated protein 1 (Keap1), 
also called inhibitor of Nrf2 (INrf2).
Whereas NF-E2 was found in erythroid cells, Nrf1 and Nrf2 
expression was observed in many tissues (90). In humans, the 
Nrf2 gene is located on chromosome 2q31 and in mice on chro-
mosome 2. Target genes of Nrf2 contain a specific binding region, 
the ARE or electrophilic response element (EpRE). The ARE 
consensus sequence is TGA(G/C)NNNGC (89). Target genes of 
Nrf2 include detoxifying enzymes and antioxidative enzymes, 
such as glutathione-S-transferase, superoxide dismutase (SOD), 
or NADPH reductase.
The Nrf2 gene consists of five exons and four introns and its 
promoter region contains two ARE sequences, indicating that 
Nrf2 controls to some extent its own expression. ARE regions are 
also found in the promoter regions of Keap1 and the small Maf 
protein MafG (91–93). The presence of an ARE sequence in the 
Keap1 gene suggests an auto-regulatory feedback loop between 
Nrf2 and Keap1 (93).
The Nrf2 protein consists of 605 amino acids in humans and 
597 amino acids in mice (90, 94), and is subdivided into six 
domains, which are evolutionary highly conserved and are termed 
Nrf2–ECH homology domains, abbreviated Neh1–6. They play 
important roles in binding to DNA, activation and inactivation 
of Nrf2. Protein structure, genetics regulation, and history of 
discovery of Nrf2 are summarized in the in-depth reviews of 
Baird and Dinova-Kostova (94), Ramkissoon et  al. (90), and 
Morita and Motohashi (89). Baird and Dinova-Kostova discuss 
5 UTR, untranslated region at the 3′ end of the mRNA. The reference single 
 nucleotide polymorphism (SNP) Cluster Report rs696 is available in the National 
Center for Biotechnology Information (NCBI) SNP database (http://www.ncbi.
nlm.nih.gov).
several possible activation and regulation mechanisms of Nrf2, 
i.e., the sequester and release model, which was used in Figure 7, 
the “dissociation of Keap1 and Cullin 3 model,” the “hinge and 
latch model,” the “Keap1 nucleocytoplasmic shuttling model,” 
and the “ubiquitination of Keap1 model,” as well as some evidence 
suggesting that Nrf2 directly senses stressors (94). In this review, 
the “sequester and release model” will be featured (Figure 7), but 
it should be mentioned that it is a significant simplification of the 
actual mechanism underlying Nrf2 regulation within cells. What 
is most important from a radiation biological point of view about 
Nrf2 and its repressor Keap1, it is the fact that the Nrf2–ARE 
pathway is redox sensitive. IR induces the formation of free 
radicals, mainly due to radiolysis of water molecules within cells.
Reactive oxygen species form adducts with DNA, proteins, 
carbohydrates, and lipids. Cells are naturally exposed to ROS due 
to metabolic processes and by other environmental cues. Cells 
possess different defense mechanisms to maintain their redox 
equilibrium by increasing the expression of antioxidative enzymes. 
The activity of Nrf2 depends on the ROS level within a cell.
Nuclear erythroid-derived 2-related factor 2 is repressed by 
the protein Keap1 under physiological conditions. Keap1 consists 
of 624 amino acids and is rich in cysteine residues (25 in mice 
and 27 in humans) (94). Keap1 binds to Nrf2 and sequesters it 
in the cytoplasm and acts as a scaffold for the Cullin 3–Rbx1-E3 
ubiquitin ligase, thereby promoting the proteasomal degradation 
of Nrf2. Under basal conditions, the half-life period of Nrf2 is 
thus only 10–30 min (90). As mentioned above, Keap1 possesses 
many cysteine residues, whose thiol groups are oxidized by 
ROS, leading to the formation of disulfide bridges. This changes 
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the conformation of Keap1, releasing Nrf2 from its binding to 
Keap1. Nrf2 then translocates to the nucleus together with co-
transcriptional factors, such as small Mafs (also belonging to the 
class of bZip transcription factors). Nrf2 forms heterodimers with 
the small Mafs, which then bind to ARE regions.
Nuclear erythroid-derived 2-related factor 2 has many interac-
tion partners: apart from the small Maf proteins (MafG, MafF, 
and MafK), another cotranscription factor is the CREB-binding 
protein (CBP). Nrf2 activity is downregulated by nuclear import 
of Keap1 where it binds Nrf2 and exports it back to the cytoplasm. 
Furthermore, the kinase Fyn phosphorylates the tyrosine residue 
568 of Nrf2, which is a signal for the nuclear export of Nrf2 (90). 
Of importance is also the interaction of Nrf2 and NF-κB. NF-κB 
competes for CBP binding and inhibits Maf kinases (95). Keap1 
was shown to contribute to the degradation of the NF-κB subunit 
p65 (96). ERK1/2-dependent pathways were suggested to medi-
ate Nrf2 activation by low-dose γ-irradiation (97).
McDonald et al. (88) investigated the impact of γ-irradiation 
on Nrf2 activity in mouse embryonic fibroblasts derived from 
Nrf2 wt and knockout (ko) mice. They analyzed the expression 
of Nrf2 target genes by quantitative real time RT-PCR (RT-qPCR) 
and Nrf2 activity by a luciferase reporter system. The reporter 
system consisted of a plasmid where a firefly luciferase gene was 
fused with a promoter containing the ARE. No significant increase 
of either target gene expression or Nrf2 activity could be observed 
in this cell line 24 h after single exposure to even a high dose of up 
to 10 Gy of γ-radiation. Yet, 5 days after irradiation, Nrf2  activity 
markedly increased and this response persisted up to 8 and 
15 days after irradiation. By shifting to a fractional irradiation over 
a time period of 5 days, a significant increase in Nrf2 target gene 
expression and increased reporter gene expression was observed 
3  h after the end of fractionated irradiation. Additionally, they 
observed no effect on cellular survival of inducing Nrf2 prior to 
irradiation in murine fibroblasts, lymphocytes, and dendritic cells 
by using different chemical activators that activate Nrf2 in a brief 
time period of a few hours. However, immortalized fibroblasts 
derived from Nrf2-ko mice were more susceptible to irradiation 
than immortalized fibroblasts derived from Nrf2 wt mice. The 
increase of ROS inside cells was delayed as well with a response 
after 5  days. The level of ROS as measured by the fluorescence 
dye 2′,7′-dichlorofluorescin diacetate (DCF-DA) only increased 
5  days after irradiation and was higher in Nrf2-ko fibroblasts, 
which moreover showed a higher basal ROS level. McDonald 
et al. (88) concluded from these results that Nrf2 is important for 
regulating long-term radiation effects and functions as a buffer 
system for maintaining the redox equilibrium in cells; a function 
than cannot be altered by exogenous chemical factors, but it is 
important for long-term cellular survival after radiation exposure. 
They speculated that long-term radiation effects may be related 
to an altered mitochondrial function, which results an increased 
production of ROS. Datta et al. (98) confirmed this for cells of the 
small intestine by exposing mice to γ-irradiation and accelerated 
iron (Fe-56, 1000 MeV/n; LET 148 keV/μm) ions. They observed 
a more potent induction of oxidative stress, DNA damage, and 
apoptosis in the small intestine of mice, which were exposed 
to energetic iron ions compared to mice that were γ-irradiated. 
Interestingly, they also observed long-term changes in the 
metabolism and gene expression in the intestinal tissue of mice 
up to 1 year after irradiation: mitochondrial function was altered 
and the level of ROS produced by mitochondrial metabolism 
increased as well as expression of NADPH oxidase, resulting in 
persistent elevated ROS level in the small intestine. Datta et al. (98) 
suspect that the induction of long-term effects after irradiation is 
important for the evaluation of chronic or late radiation effects.
Jayakumar et al. (99) found a connection between differences 
in Nrf2 expression and radiation resistance in the two different 
prostate cancer cell lines PC3 and DU145. Both cell lines were 
exposed to γ-radiation and Nrf2 content was measured prior to 
and after irradiation. Both cell lines differed in Nrf2 expression 
under basal conditions. It was found that cellular survival was 
higher after irradiation in the cell line DU145, which showed a 
higher basal Nrf2 activity. Furthermore, the level of basal and 
induced ROS after irradiation was higher in PC3 cells, which in 
contrast to DU145 exhibited a lower basal activity of Nrf2. In both 
cell lines, Nrf2 protein content increased after irradiation, whereas 
the protein level of Keap1 was reduced. Also, the expression of 
antioxidant enzymes increased after irradiation in both cell lines, 
but this response was significantly stronger in the DU145 cell line. 
Cellular survival was reduced in both cell lines and especially in the 
cell line with low basal Nrf2 expression PC3, after exposure to the 
chemical Nrf2 inhibitor retinoic acid. This outcome was enhanced 
when Nrf2 was knocked down on transcript level by transfecting 
both cell lines with small interfering RNA (siRNA) against Nrf2. 
These findings indicate that Nrf2 is important for cellular survival 
after exposure to IR and that radiation resistance of different 
cell lines, especially cancer cell lines depends upon differences 
in basal Nrf2 activity and upregulation of Nrf2. Examining the 
expression of Nrf2 in tumor tissue may therefore be important for 
the planning and predicting the outcome of therapeutic irradia-
tion. Furthermore, as predominantly antioxidant enzymes were 
upregulated, there seems to be an association between oxidative 
stress and cellular survival after irradiation. Independently from 
radiation biological considerations, Wang et al. (100) showed that 
Nrf2 is antagonized by retinoic acid receptor α (RARα) in the small 
intestine of mice after treatment with retinoic acid, this opens the 
possibility to modulate Nrf2 activity chemically. Mathew et  al. 
(101) showed that the Nrf2 activator sulforaphane (which also 
shows anti-cancerous effects) protects fibroblasts against IR.
In a similar setting, Patwardhan et al. (102) showed that T cell 
lymphoma EL-4 cells exhibit a high basal Nrf2 activity, show 
lower ROS levels than non-tumorigenic cells and that enhanced 
radiation resistance is linked to higher Nrf2 activity. siRNA 
against Nrf2 or treatment with all-trans retinoic acid (ATRA also 
called Tretinoin as a pharmaceutical) enhanced radiosensitivity 
of EL-4 cells.
Apart from IR, such as X-rays and γ-radiation, Nrf2 was also 
shown to be activated by UV radiation (103). Dermal fibroblasts 
showed an increased accumulation of Nrf2 in the nucleus after 
exposure to UV-A irradiation, but not after UV-B irradiation. 
Moreover, fibroblasts derived from Nrf2-ko mice exhibited a 
1.7-fold increase in apoptosis after UV-A exposure compared 
to fibroblasts derived from wt mouse. The opposite effect was 
observed in Keap1-ko fibroblasts; here, the apoptosis rate was half 
of the rate observed in fibroblasts isolated from wt mice.
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Nuclear erythroid-derived 2-related factor 2 also seems to be 
important for the function adult stem cells. Hochmuth et al. (104) 
showed that inactivation of the Nrf2 analog CncC in Drosophila 
was required for the maturation of intestinal stem cells. CncC is 
constitutively active in intestinal stem cells and its inactivation 
by Keap1 is a signal for intestinal stem cell proliferation. They 
observed that increased ROS levels lead to increased prolifera-
tion of intestinal stem cells, a similar effect could be observed by 
knocking down CncC with siRNA. This work indicates that the 
activation pattern of CncC is reversed in stem cells compared 
with differentiated cells. Whereas in differentiated cells ROS acti-
vate CncC or Nrf2, in intestinal stem cells CncC is inactivated by 
ROS to allow for an increased proliferation of intestinal stem cells 
to renew the intestinal tissue. This seems to imply an activation 
mode of Nrf2 that depends on cell type and developmental stage. 
How oxidative stress inactivates Nrf2 in intestinal stem cells 
remains to be investigated. Tsai et al. (105) could confirm the role 
of Nrf2 in controlling stem cell proliferation. They confirmed the 
findings of Hochmuth et al. (104) in hematopoietic stem cells. 
Reduced Nrf2 activity or lack of Nrf2 led to hyperproliferation 
of stem cells and progenitor cells. This was accompanied by a 
reduced self-renewal of hematopoietic stem cells and reduction 
of quiescence. Nrf2 proved to be a crucial factor in the regula-
tion and function of hematopoietic stem cells. Whereas both 
studies did not involve radiation, Kim et al. (106) showed that 
Nrf2 contributes strongly to the survival of hematopoietic stem 
cells in a mouse model of total body γ-irradiation. Nrf2-ko mice 
had a lower survival and a higher impairment of hematopoietic 
function compared to Nrf2 wt mice. Furthermore, activation 
of Nrf2 prior to irradiation increased overall survival of mice 
after TBI. Additionally, hematopoiesis was increased in mice, 
which were treated with the Nrf2 activator 2-trifluoromethyl-
2-methoxychalone (TMC).
Recently, Large et al. (107) investigated the role of Nrf2 in the 
low-dose response of ECs. Surprisingly, they found a decreased 
expression of Nrf2 after low-dose X-irradiation (0.5  Gy) in 
EA.hy926 ECs and primary human dermal microvascular ECs 
(HMVEC), additionally the DNA binding of Nrf2 was lowered. 
The expression of Nrf2 target genes and the activity of Nrf2 itself 
followed a non-linear pattern of expression, meaning that the 
observed level of mRNA increased and decreased interchange-
ably with increasing doses (0, 0.3, 0.5, 0.7, and 1  Gy). In all 
cases, the expression of glutathione peroxidase (GPx) and SOD 
as well as the Nrf2 binding activity were lowest after 0.5  Gy 
X-irradiation. This finding is interesting, as it indicates that 
at least in these cell lines low-dose irradiation may induce an 
unusual pattern of Nrf2 expression and activity and that certain 
doses may decrease Nrf2 activity. As they treated cells prior to 
irradiation with TNF-α to simulate inflammation, there might 
be an involvement of NF-κB, as TNF-α activates it, in the expres-
sion and activity pattern of Nrf2.
Relatively little is known about the role of Nrf2 in the cellular 
radiation response to heavy ion irradiation. Quite recently, Xie 
et  al. (108) showed that curcumin (an Nrf2 activator) reduces 
cognitive impairment in mice after exposure carbon ions (4 Gy). 
They observed an upregulation of Nrf2 and Nrf2 downstream 
genes, NAD(P)H quinine oxidoreductase 1 (NQO1), heme 
oxygenase-1 (HO-1), and γ-glutamyl cysteine synthetase (γ-
GCS) in the brain tissue of mice that were treated with curcumin. 
Kim et al. (109) found increased survival of colonic epithelial cells 
after exposure to iron ions (Fe-56) when Nrf2 was activated prior 
to radiation exposure. They focused on the interaction of Nrf2 
and p53 binding protein 1 (p53BP1), as p53BP1 contains three 
ARE sequences. Activation of Nrf2 in colon epithelial cells prior 
to irradiation reduced the frequency of G1 and S/G2 chromo-
some aberrations. In general, the DDR was enhanced by Nrf2 
activation.
The response of Nrf2 to radiation may be an important factor 
in tumor therapy. Mutations in Nrf2 and Keap1 are known to 
occur in various cancer cell lines and to confer protection to 
cancer cell lines toward chemo- or radiotherapy. Some cancer 
cell lines possess a high basal activity of Nrf2, which increases 
their resistance against radiation (110). In general, Nrf2 is accu-
mulated in tumors and high levels of Nrf2 expression lead to a 
poor prognosis for cancer patients (111). In a lung cancer study, 
samples were taken from 178 lung squamous cell carcinomas 
(SqCCs) (112, 113) and, apart from 53BP1, most mutations were 
found in three genes associated with the Nrf2–ARE pathway, 
NFE2L2 (the gene name of Nrf2), Keap1, and Cul3 (the gene 
name of Cullin 3). Increased resistance to radiation therapy was 
linked to a high level of Nrf2.
Further studies of the function and activity of Nrf2 after expo-
sure of cells to heavy ions, especially carbon ions, may give hints 
how to improve radiation therapy and will be of significance for 
the planning of long-term human space missions.
ROLe OF OTHeR TRANSCRiPTiON 
FACTORS iN THe CeLLULAR RADiATiON 
ReSPONSe
In addition to the two key transcription factors in the cellular 
damage response, p53 and NF-κB, and the oxidative stress-
induced Nrf2, several other transcription factors are activated 
in response to IR exposure (Figure  2). ATM-mediated phos-
phorylation of c-Abl appears to increase the transcription of 
stress response genes via activation of Jun kinase (15). Also, 
other MAPK pathways are activated, resulting, e.g., in forma-
tion of the transcription factor activated protein 1 (AP-1), 
which controls proliferation, senescence, differentiation, and 
apoptosis via growth factors (114). Cataldi et al. (115) propose 
a role for the transcription factor cyclic adenosine monophos-
phate (cAMP)-responsive element-binding protein (CREB) in 
survival responses of Jurkat T-cells after exposure to IR. The 
transcription factor Sp1, which is involved in cell differentiation, 
cell growth, apoptosis, immune responses, response to DNA 
damage, and chromatin remodeling, is rapidly phosphorylated 
in response to DNA damage, but this phosphorylation did not 
affect its transcriptional activity (116). The colocalization of 
phosphorylated Sp1 with activated ATM kinase in nuclear foci 
was interpreted as a sign for a role of Sp1 in DNA repair (116). A 
colocalization in nuclear foci was also observed for the forkhead 
box-O 3 (FOXO-3) transcription factor that is involved in cell-
cycle control (117).
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cAMP-Responsive element-Binding 
Protein
cAMP-responsive element-binding protein (CREB) is a 43-kDa 
bZIP nuclear transcription factor involved in cAMP signal-
ing (115). Its activation via phosphorylation leads to binding 
of the transcription factor to the cAMP-responsive element 
(CRE), a highly conserved sequence, inducing transcription of 
target genes for several cellular functions, including regulation 
of apoptosis and proliferation (118, 119). CREB phosphorylation 
is cell type and stimulus dependent. It is therefore possible for a 
wide range of molecules to activate the transcription factor. PKA, 
PKB, and ERK/MAPK phosphorylate CREB at Serine 133 (119, 
120), whereas ATR and ATM phosphorylate the factor at Serine 
111 and 121, respectively, in response to IR and oxidative stress 
(121, 122).
Sparsely IR is able to increase the binding of CREB to its 
consensus sequence (123). Furthermore, γ-irradiation has been 
shown to induce phosphorylation of CREB, thereby activating it 
(115, 119). Radiation-induced activation of CREB is connected 
with survival, as its target genes promote cellular proliferation, 
such as cyclin A, cyclin D1, proliferating cell nuclear antigen 
(PCNA), c-fos, and COX-2. In CREB knockdown studies, 
survival decreased (124). Co-incidental with CREB activation is 
low caspase-3 activity and a lack of Bax and Bcl2 level difference, 
further supporting an anti-apoptotic role (119).
Although an increase of ERK/MAPK expression after irradia-
tion with carbon ions (125) and α-particles (126) was shown, no 
connection to CREB activation has been made. Therapeutic high 
LET studies lost their focus on CREB as survival factor, but it 
can be said that with the upcoming trend of therapeutic irradia-
tion using heavy ions, CREB should be considered as means to 
increase radiosensitivity in tumor cells.
Activated Protein 1
Activated protein 1 (AP-1) is a transcription factor formed by 
homo- or heterodimerization of proteins of the Jun family (c-Jun, 
JunB, and JunD) or the Fos family (c-Fos, FosB, Fra-1, and Fra-
2). Such dimers (AP-1 complexes) are able to recognize AP-1 
binding sites containing the 12-O-tetradecanoylphorbol-13-
acetate (TPA) response element (TRE), its DNA target sequence 
(127). C-jun regulates the expression of cyclin D1, a promoter 
of cell-cycle progression into G1-phase (128, 129). In addition 
to genes regulating cell-cycle progression, AP-1 controls its own 
expression, having a TRE in the promoter region of the c-jun 
gene (130).
The transcriptional activity of c-Jun can be enhanced by phos-
phorylation of Serine 63 and 73 by JNK. It has been shown that 
c-Jun is phosphorylated by JNK in the nucleus after γ-irradiation 
(Figure  2). Furthermore, the same study showed increased 
DNA-binding activity of AP-1 in response to sparsely IR with 
AP-1 complexes containing c-Jun as well as JunD and JunB 
(131). X-radiation has also been shown to increase DNA-binding 
 activity of AP-1 (132). Exposure to an 18  MeV electron beam 
(4 Gy) activated AP-1 in HepG2 cells (133).
Elevated gene expression of c-jun and protein expression 
of AP-1-associated factors (c-jun, c-fos, Fra1, and JNK2) 
was observed in response to α-particles exposure (134, 135). 
Binding activity of AP-1 increased after irradiation with very 
low doses of α-particles (6  mGy). This binding was inhibited 
by SOD indicating a response of AP-1 to oxidative stress (126). 
Iron ion (Fe-56, 1000 MeV/n, LET 148 keV/μm) irradiation has 
been associated with proliferation of intestinal epithelium cells, 
connecting irradiation-induced oxidative stress with activation 
AP-1 (98).
Reactive oxygen species and other radiation-released free 
radicals can stimulate JNK and AP-1 activity (23), therefore 
promoting cell-cycle progression, although influence in apoptosis 
induction has also been reported (136). Additionally, the radia-
tion-induced activation of AP-1 was also correlated to increased 
levels of glutamylcysteine synthetase, which is directly associated 
with synthesis of glutathione, a cellular radical scavenger (133). 
Therefore, AP-1 might be relevant in high LET radiation therapy 
by enhancing the cellular defense against ROS and regulation the 
cellular apoptotic response to radiation.
Specificity Protein 1
The Sp1 belongs to the specificity protein/Krüppel-like factor 
(Sp/XKLF) family of transcription factors that contain 3 con-
served Cys2His2 zinc fingers for DNA binding (137). Loss of 
these zinc fingers abolishes not only DNA-binding capacity but 
also nuclear translocation (138). Sp1 is ubiquitously expressed 
in all mammalian cells and regulates cellular functions, such 
as apoptosis, cell-cycle progression, growth/proliferation, and 
metabolism (137, 139). The fate of Sp1 differs greatly depending 
on its posttranslational modification. Many different proteins 
modify Sp1 through all stages of the cell cycle via SUMOylation, 
glycosylation, ubiquitination, acetylation, or phosphorylation. 
Overexpression of Sp1 regulates apoptosis in a p53-dependent 
manner after suppression of cell growth (137).
ATM can activate Sp1 via phosphorylation in response to 
X-rays and H2O2 (140), which is recruited to DNA DSB and 
can promote repair in a non-transcriptional manner (141). Sp1 
acts also in a transcriptional manner upon IR, as it is associ-
ated with coordination of cellular response after treatment with 
γ-rays, activated by DNA-PK through phosphorylation (142). 
Furthermore, an increased nuclear expression of Sp1 has been 
observed for irradiation with 20  Gy X-rays (143) as well as 
increased binding activity upon γ-irradiation (123, 144).
Microarray gene expression experiments assume activation of 
Sp1 in cells irradiated with α-particles (LET 123 keV/μm), and 
its involvement in subsequent cellular responses of directly and 
indirectly exposed (bystander) cells (145). The Sp1-dependent 
gene expression profile included up- and downregulation of 
16 and 6 genes, respectively, in cells directly hit by α-particles, 
while upregulation of a smaller subset (10 genes) dominated in 
bystander cells (145). As with sparsely IR, Sp1 could act in a more 
administrative manner upon high LET radiation, as DNA-PK is 
strongly activated after carbon and iron ion exposure (146).
Sp1 has various roles in the DDR, ranging from orchestrating 
the response, to actively regulating apoptosis or repair. For cancer 
treatment with carbon ions, Sp1 is well worth investigating, as 
there are not many distinct approaches to study this versatile 
transcription factor in context of high LET particle irradiation.
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early Growth Response 1
The transcription factor early growth response 1 (EGR-1) is 
a member of the EGR family and is suggested to act as anti- 
proliferative signal for tumor cells, as well as an apoptotic enhancer 
(147). It has been shown to be activated by X- (147) and γ-rays 
(148). Radiation-induced activation of EGR-1 is associated with 
ROS (148). Upon irradiation, EGR-1 can act p53-independently 
as mediator for TNF-α-induced apoptosis (147). Gene expres-
sion of EGR-1 has been found to be increased also in response 
to irradiation with α-particles (134). The role of EGR-1 in the 
cellular radiation response is pro-apoptotic and in light of heavy 
ion radiation therapy, it would be instructive to know the extent 
of its pro-apoptotic capabilities upon high LET irradiation.
iNFLUeNCe OF LiNeAR eNeRGY 
TRANSFeR ON TRANSCRiPTiON 
FACTOR ACTivATiON
The cellular response to high LET radiation shows quantitative 
and in some aspects qualitative differences compared to the 
low LET radiation response. For different radiation types, the 
biological effects, observed at the same absorbed dose, depend 
on their quality (sparsely or densely IR). Comparison of the 
biological effects of different radiation qualities is usually being 
performed in terms of relative biological effectiveness (RBE).6 
In radiotherapy, the RBE is not only of highest interest for cell 
killing but also for late effects such as cancerogenesis (149). For 
the various biological endpoints, the RBE can depend on many 
factors, such as LET, dose rate, dose fractionation, radiation dose, 
and type of the irradiated cells or tissues.
One of the earliest systematic studies of the dependence of 
RBE on LET showed that the RBE reached a maximum at an 
LET of 100–200 keV/μm for survival of human kidney T1 cells 
after irradiation with deuterium ( 1
2 H) and α-particles (151–153). 
Thereafter, an LET–RBE function was determined for many 
biological endpoints and reached a maximum at with an LET 
from 90 to 200 keV/μm (154–157). In these studies, the RBE for 
mutation induction was higher compared to inactivation for all 
examined LETs (154). In HEK cells, the maximal RBE for repro-
ductive cell death was 2.5 (158). For LETs above 900  keV/μm, 
RBE values for reproductive cell death dropped to 1 or below 
1. Stoll et al. (159) also found an RBE for inactivation by high 
LET lead ions (>10,000 keV/μm) far below 1 and for nickel ions 
(>1000  keV/μm) around 1. In a human neuronal progenitor 
cell line (Ntera2), the RBEmax for apoptosis 48  h after iron ion 
exposure (1 GeV/n) was at least 3.4 (160). The RBE for induction 
6 The absorbed dose of a test radiation necessary to induce a defined biological end-
point and a defined severity of this endpoint (survival, cell cycle arrest, mutagen-
esis, chromosome aberrations, tumor induction in laboratory animals, and others) 
is compared to the dose of a reference radiation needed for induction of the same 
biological effect (150). Sparsely ionizing radiation such as γ-rays or X-rays is often 
used as reference radiation. In some cases, protons are applied as reference. The 
RBE is calculated according to the following  formula:
 
RBE
Absorbed dose of reference radiation inducing biologic
=
 effect (Gy)
Absorbed dose of test radiation inducing biologic effect (Gy)
of double-strand breaks was determined to be 1.8 for iron ions 
compared to X-rays, as detected by immunostaining of γ-H2AX 
0.5 h after radiation exposure (161), or by pulsed-field gel elec-
trophoresis (162) or other methods such as alkaline elution (163). 
For α-particles (LET 27–124 keV/μm), it ranged between 1.2 and 
1.4 (164).
For improvement of cancer therapy, studies with several cancer 
cells and with various heavy ions, especially carbon ions, had been 
performed. In a microarray analysis of oral SqCC cells, 84 genes 
were identified that were modulated by carbon and neon ion (LET 
~75 keV/μm) irradiation at all doses (1, 4, and 7 Gy) (165). Among 
these genes, three genes (TGFBR2, SMURF2, and BMP7) were 
found to be involved in the transforming growth factor β signaling 
pathway and two genes (CCND1 and E2F3) in the cell-cycle G1/S 
checkpoint regulation pathway. The relevance of these results for 
normal tissues cells or non-cancer cell lines has to be determined. 
In normal skin tissue, low doses (0.01 and 1 Gy) of IR resulted in 
transient alterations in the expression of genes involved in DNA 
and tissue remodeling, cell-cycle transition, and inflammation 
(TNF, interleukins) (166), suggesting an involvement of the NF-κB 
pathway, the main inflammatory pathway, in the cellular response 
to IR. As exposure to accelerated argon ions (95 MeV/n Ar, LET 
271  keV/μm) resulted in strong activation of NF-κB in human 
cells (167), the RBE for NF-κB activation by heavy ions of differ-
ent LET was determined (158). NF-κB-dependent gene induction 
after exposure to heavy ions was detected in stably transfected 
human 293 reporter cells. For comparison, cells were exposed 
to 150  kV X-rays. The maximal biologic effect ranged between 
70 and 300 keV/μm. Argon ions (271 keV/μm) had the maximal 
potency (RBE ~9) to activate NF-κB-dependent gene expression 
in HEK cells. The effect of carbon ions was less pronounced and 
comparable the activation observed after X-ray exposure (168). 
Inhibition of ATM resulted in complete abolishment of NF-κB 
activation by X-rays and heavy ions. Therefore, NF-κB activation 
in response to heavy ions is ATM dependent and seems to be 
mediated by a nuclear signal from the damaged DNA as described 
for the genotoxin-induced NF-κB subpathway.
Assuming that NF-κB activation promotes survival, it can be 
hypothesized that the extreme capacity of energetic heavy ions in 
the LET range of 70–300 keV/μm to activate NF-κB’s transcrip-
tional effects might be responsible for the lower relative effective-
ness in cell killing observed in this range. Above 300 keV/μm, the 
overkill effect (meaning that with further increase of the deposited 
energy in a small volume of the cell no more biologically relevant 
damages can be caused) possibly results in a decrease of the RBE.
Other groups report NF-κB translocation after exposure of 
normal human monocytes (MM6 cells) to 0.7 Gy of 56Fe ions using 
a DNA-binding assay (169). This clearly indicates that high LET 
iron ion exposure induces rapid and persistent NF-κB activation. 
This activation of NF-κB was shown to be mediated through phos-
phorylation of IκBα and the subsequent proteasome-dependent 
degradation pathway. The iron study only revealed binding of 
NF-κB to its consensus sequence of 5′-GGGGACTTTCC-3′, and 
not transcriptional activation.
Scarce LET dependence data exist for p53 expression in 
human neuronal progenitor cells (160). Screening of gene expres-
sion in the nematode Caenorhabditis elegans suggests an LET 
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dependence or track structure dependence of the gene expression 
changes (170). In human lens epithelial cells, transcription and 
translation of CDKN1A [p21CIP1/WAF1] are both temporally regu-
lated after exposure to 4 Gy of high-energy accelerated iron-ion 
beams (~150  keV/μm) as well as to protons (~1  keV/μm) and 
X-rays, whereby the magnitude and kinetics of the expression 
enhancement seem to depend on the LET of the radiation (171).
CONCLUSiON
Increased understanding of signaling pathways leading to tran-
scription factor activation or inhibition in response to high LET 
radiation exposure will help to identify and make use of new 
targets for radiosensitization of tumor tissue and/or increasing 
radioresistance of surrounding normal tissue. The question which 
transcription factor offers a suitable target for charged particle 
cancer therapy is still open, as very few studies on transcription 
factor activation by carbon ions in tumor cells were performed. 
Also, not in all studies clinically relevant doses were applied, 
and extrapolation of the effects from high to lower doses is not 
constructive when the dose–response curves are unknown.
Although the role of p53 seems to be quite clear in low 
LET radiation therapy with increased radiosensitivity in case 
of functionality, this is not yet the case for charged particle 
therapy. Some studies suggest p53-independent cell killing by 
high LET which is a large advantage for treatment of tumors 
with p53 mutations. More studies with different cancer cell types 
are required. Concerning surrounding tissues, p53 inhibition 
might prevent precipitous apoptosis in apoptosis prone tissues. 
In tissues where p53-induced cell-cycle arrest dominates, p53 
inhibition might impede this protective pathway and have 
detrimental effects.
The anti-apoptotic effects of NF-κB could support tumor cell 
survival during chemo- or radiotherapy; therefore, NF-κB is an 
interesting target for combined cancer therapies including carbon 
ion therapy. In several tumor cell types, inhibition of NF-κB 
resulted in radiosensitization. Activation of NF-κB in the normal 
tissue might not only limit detrimental effects by cell killing but 
also promote inflammation.
The activity of Nrf2 after irradiation seems to follow a compli-
cated pattern, i.e., different time scales seem to be involved, and 
most striking is the occurrence of long-term effects in fibroblasts 
and intestinal epithelial cells. In the case of intestinal epithelial 
cells, the occurrence of long-term oxidative stress points to 
an inefficient activation of Nrf2 or a reduced oxidative stress 
response. It would be interesting to investigate this further. Of 
particular interest would be to compare differentiated cells with 
tissue-specific stem cells after irradiation; as in the case of intes-
tinal stem cells, some studies suggest that oxidative stress inhibits 
the action of Nrf2 and that here might be differences between 
fully differentiated cells and stem cells in the regulation of Nrf2. 
Another open question is how to modulate the Nrf2 response in 
healthy tissue for radiation protection to reduce the side effects 
of radiation therapy and to mitigate radiation effects in spaces in 
case of manned missions. Modulating the elevated level of Nrf2 
activity in cancer cells may be beneficial for cancer therapy. As 
described above, Nrf2 is upregulated in many cancer tissues and 
a high level of Nrf2 expression corresponds to a poor prognosis 
for patients. In this sense, Nrf2 can serve as an indicator for the 
outcomes of cancer radio- and chemotherapy. So far, relatively 
little is known about chemicals that may inhibit Nrf2 directly 
(apart from retinoic acid) or upregulate Keap1, research in this 
direction may lead to the discovery of novel drug candidates 
supplementing radiation therapy. Using siRNA for therapeutic 
means may also be an option for those cancers that show a high 
expression and activity of Nrf2.
CREB, AP-1, Sp1, and EGR-1 (or up- or downstream events 
in these pathways) were activated by low doses of high LET 
α-particles and the first three were also shown to be involved in 
the cellular response to carbon and/or iron ions. For low LET 
radiation, many studies suggest a subordinate importance of 
these factors in cellular radiation responses compared to p53, 
NF-κB, and Nrf2. Nevertheless, we discuss how modification of 
these transcription factors may influence therapy results.
CREB itself is a factor inducing cellular survival, activated by 
phosphorylation due to (among others) ATM. Amorino et  al. 
(124) detected a decreased survival of CREB-ko cells after IR 
exposure compared to wt cells. As also high LET irradiation 
stimulates ATM kinase activity, which in turn can activate CREB, a 
potential therapy approach is to inhibit phosphorylation of CREB 
or its binding to DNA in the vicinity of cancerous tissue. This 
can be accomplished through siRNA or other CREB-inhibiting 
substances, which are then applied directly to target tissue (in 
case of superficial tumors) or transported to the tumor via hom-
ing probes (in case of hard-to-reach tumors). After reducing 
the survivability of the tumor in such a way, radiation-induced 
apoptosis via p53-dependent and -independent mechanisms can 
fight the tumor more effectively.
This approach bears the problem that, with drug-induced 
inhibition of CREB in tumor vicinity, also non-transformed tis-
sue may be affected and therefore more susceptible for radiation-
induced cell death. In this case, the high fidelity of dose deposition 
in heavy ion therapy may prove advantageous.
AP-1 is a sensory factor for oxidative stress and is activated 
by ROS and other free radicals besides IR (low LET like X- and 
γ-rays as well as high LET α particles). This activation can lead 
to apoptosis; therefore, a supplementary approach in heavy ion 
therapy would be to enrich AP-1 in tumor tissue, delivered as 
mentioned above, so that more AP-1 is activated by high LET 
radiation and apoptosis is induced more effectively in tumor cells. 
C-abl is a negative regulator of γH2AX and can induce apoptosis 
in a p53-independent manner. Therefore, a supplementary strat-
egy for heavy ion therapy is again enrichment of the protein to 
increase apoptotic induction and weaken repair of damaged DNA 
in tumor cells.
Sp1 is, besides other functions, a regulator for apoptosis and 
the orchestration of the DDR and can initiate repair of DNA dam-
ages. An obvious strategy to reinforce high LET radiation effects 
would be inhibition of Sp1. However, the transcription factor 
assumes many various roles within the cell, so that manipulation 
of Sp1 might result in unwanted side effects. Genes regulated 
by Sp1 might be better targets for combating tumors and their 
expression in tumor cells in response to heavy ion irradiation 
should be analyzed.
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